SRZN vs PRTA

For growth investors, Surrozen, Inc.

(SRZN) is the stronger pick with -67. 4% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Surrozen, Inc. (SRZN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Prothena Corporation plc (PRTA) delivered a total return of -57.

2%, compared to -79. 2% for Surrozen, Inc. (SRZN). Over 10 years, the gap is even starker: PRTA returned -72. 5% versus SRZN's -80. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Surrozen, Inc.

(SRZN) is the lower-risk stock at 0. 88β versus Prothena Corporation plc's 0. 96β — meaning PRTA is approximately 8% more volatile than SRZN relative to the S&P 500.

By revenue growth (latest reported year), Surrozen, Inc.

(SRZN) is pulling ahead at -67. 4% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Surrozen, Inc. grew EPS -49. 4% year-over-year, compared to -99. 6% for Prothena Corporation plc. Over a 3-year CAGR, SRZN leads at -34. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Prothena Corporation plc (PRTA) is the more profitable company, earning -25.

2% net margin versus -69. 6% for Surrozen, Inc. — meaning it keeps -25. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SRZN leads at -1210. 6% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — SRZN leads at 84. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRTA: 80.

4% to $19. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Surrozen, Inc.

(SRZN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88)). Both have compounded well over 10 years (SRZN: -80. 9%, PRTA: -72. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.